BACKGROUND: The ACOSOG Z0011 trial demonstrated that axillary dissection (ALND) is not necessary for local control or survival in women with T1/2cN0 cancer undergoing breast-conserving therapy. There is concern about applying these results to triple-negative (TN) cancers secondary to their high local-recurrence (LR) rate. We examined the frequency of lymphovascular invasion (LVI) and nodal metastases in TN cancers to determine whether ALND can be safely avoided in this subtype. METHODS: Data were obtained from a database of patients with invasive breast cancer treated at Memorial Sloan Kettering Cancer Center from January 1998 to December 2010. A total of 11,596 tumors were classifiable into clinical surrogates for molecular subtype by immunohistochemical analysis: hormone receptor (HR)+/HER2+, HR+/HER2-, HR-/HER2+, and TN (HR-/HER2-). Multivariable logistic regression analysis (MVA) was used to determine associations between clinicopathologic variables and subtype. RESULTS: There were differences in age, tumor size, LVI, grade, and nodal involvement among groups. On MVA controlling for size, grade, and age, ER, PR, and HER2 status were significantly associated with LVI (p < 0.0001). Relative to TN tumors, HR+/HER2-, HR+/HER2+, and HR-/HER2+ tumors had higher odds of demonstrating LVI of 1.8 (odds ratio 1.8; 95 % confidence interval 1.6-2.1), 2.5 (2.5; 2.0-3.0), and 1.7 (1.7; 1.4-2.1), respectively. On MVA adjusting for size, grade, LVI, and age, TN tumors had the lowest odds of having any or high-volume nodal involvement (≥4 nodes, p < 0.0001). CONCLUSIONS: LVI and nodal metastases were least frequent in TN cancers compared with other subtypes, despite the uniformly worse prognosis and increased LR rate in TN tumors. This suggests TN cancers spread via lymphatics less frequently than other subtypes and ALND may be avoided in TN patients meeting Z0011 eligibility criteria.
BACKGROUND: The ACOSOG Z0011 trial demonstrated that axillary dissection (ALND) is not necessary for local control or survival in women with T1/2cN0cancer undergoing breast-conserving therapy. There is concern about applying these results to triple-negative (TN) cancers secondary to their high local-recurrence (LR) rate. We examined the frequency of lymphovascular invasion (LVI) and nodal metastases in TN cancers to determine whether ALND can be safely avoided in this subtype. METHODS: Data were obtained from a database of patients with invasive breast cancer treated at Memorial Sloan Kettering Cancer Center from January 1998 to December 2010. A total of 11,596 tumors were classifiable into clinical surrogates for molecular subtype by immunohistochemical analysis: hormone receptor (HR)+/HER2+, HR+/HER2-, HR-/HER2+, and TN (HR-/HER2-). Multivariable logistic regression analysis (MVA) was used to determine associations between clinicopathologic variables and subtype. RESULTS: There were differences in age, tumor size, LVI, grade, and nodal involvement among groups. On MVA controlling for size, grade, and age, ER, PR, and HER2 status were significantly associated with LVI (p < 0.0001). Relative to TN tumors, HR+/HER2-, HR+/HER2+, and HR-/HER2+ tumors had higher odds of demonstrating LVI of 1.8 (odds ratio 1.8; 95 % confidence interval 1.6-2.1), 2.5 (2.5; 2.0-3.0), and 1.7 (1.7; 1.4-2.1), respectively. On MVA adjusting for size, grade, LVI, and age, TN tumors had the lowest odds of having any or high-volume nodal involvement (≥4 nodes, p < 0.0001). CONCLUSIONS: LVI and nodal metastases were least frequent in TN cancers compared with other subtypes, despite the uniformly worse prognosis and increased LR rate in TN tumors. This suggests TN cancers spread via lymphatics less frequently than other subtypes and ALND may be avoided in TN patients meeting Z0011 eligibility criteria.
Authors: Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: Giuseppe Viale; Stefano Zurrida; Eugenio Maiorano; Giovanni Mazzarol; Giancarlo Pruneri; Giovanni Paganelli; Patrick Maisonneuve; Umberto Veronesi Journal: Cancer Date: 2005-02-01 Impact factor: 6.860
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Paul L Nguyen; Alphonse G Taghian; Matthew S Katz; Andrzej Niemierko; Rita F Abi Raad; Whitney L Boon; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544
Authors: Simon J Crabb; Maggie C U Cheang; Samuel Leung; Taina Immonen; Torsten O Nielsen; David D Huntsman; Chris D Bajdik; Stephen K Chia Journal: Clin Breast Cancer Date: 2008-06 Impact factor: 3.225
Authors: Anita Mamtani; Sujata Patil; Kimberly J Van Zee; Hiram S Cody; Melissa Pilewskie; Andrea V Barrio; Alexandra S Heerdt; Monica Morrow Journal: Ann Surg Oncol Date: 2016-05-11 Impact factor: 5.344
Authors: Jana de Boniface; Marcus Schmidt; Jutta Engel; Marjolein L Smidt; Birgitte Vrou Offersen; Toralf Reimer Journal: Breast Care (Basel) Date: 2018-09-05 Impact factor: 2.860
Authors: Andrea Angius; Giovanna Pira; Paolo Cossu-Rocca; Giovanni Sotgiu; Laura Saderi; Maria Rosaria Muroni; Patrizia Virdis; Daniela Piras; Rallo Vincenzo; Ciriaco Carru; Donatella Coradduzza; Maria Gabriela Uras; Pierina Cottu; Alessandro Fancellu; Sandra Orrù; Paolo Uva; Maria Rosaria De Miglio Journal: J Cancer Res Clin Oncol Date: 2022-08-28 Impact factor: 4.322
Authors: Matthew S Katz; Linda McCall; Karla Ballman; Reshma Jagsi; Bruce G Haffty; Armando E Giuliano Journal: Breast Cancer Res Treat Date: 2020-02-10 Impact factor: 4.872
Authors: Carlos Martin Loza; Pablo Mandó; Carolina Ponce; Federico Coló; Veronica Fabiano; Jose Loza; Maria Victoria Costanzo; Adrian Nervo; Jorge Nadal; Anibal Nuñez de Pierro; Reinaldo Chacon; Rcm Database Contributors Journal: Breast Care (Basel) Date: 2018-07-13 Impact factor: 2.860
Authors: Aryana M Razmara; Elodie Sollier; Grace N Kisirkoi; Sam W Baker; Margot B Bellon; Alex McMillan; Clementine A Lemaire; Vishnu C Ramani; Stefanie S Jeffrey; Kerriann M Casey Journal: Clin Exp Metastasis Date: 2020-04-25 Impact factor: 5.150